Pfizer's Covid Product Sales Surge, Cost Cuts Boost Earnings
Generated by AI AgentMarcus Lee
Tuesday, Feb 4, 2025 7:29 am ET1min read
FDS--
Pfizer Inc. (NYSE: PFE) reported fourth-quarter and full-year 2024 earnings that topped analysts' estimates, driven by stronger-than-expected sales of its Covid-19 products and the benefits of cost-cutting measures. The pharmaceutical giant's shares rose 2% in early trading on Wednesday.
For the fourth quarter, Pfizer reported adjusted diluted earnings per share (EPS) of 63 cents, surpassing the FactSet consensus estimate of 46 cents. Revenue came in at $17.76 billion, slightly ahead of the $17.36 billion estimate. The company's full-year 2024 EPS is expected to be in the range of $2.80 to $3.00, with revenue projected between $61.0 billion and $64.0 billion.
Pfizer's Covid-19 products, Comirnaty and Paxlovid, generated $17.76 billion in revenue for the year, up 22% from the same period last year. The company attributed the strong performance to higher-than-expected sales of its Covid-19 products, which offset a decline in revenue from other products.
PFE--
Pfizer Inc. (NYSE: PFE) reported fourth-quarter and full-year 2024 earnings that topped analysts' estimates, driven by stronger-than-expected sales of its Covid-19 products and the benefits of cost-cutting measures. The pharmaceutical giant's shares rose 2% in early trading on Wednesday.
For the fourth quarter, Pfizer reported adjusted diluted earnings per share (EPS) of 63 cents, surpassing the FactSet consensus estimate of 46 cents. Revenue came in at $17.76 billion, slightly ahead of the $17.36 billion estimate. The company's full-year 2024 EPS is expected to be in the range of $2.80 to $3.00, with revenue projected between $61.0 billion and $64.0 billion.
Pfizer's Covid-19 products, Comirnaty and Paxlovid, generated $17.76 billion in revenue for the year, up 22% from the same period last year. The company attributed the strong performance to higher-than-expected sales of its Covid-19 products, which offset a decline in revenue from other products.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet